Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SREBF1 | P36956 | 2/20 | 0.35 |
| ▸ | CYP24A1 | Q07973 | 4/20 | 0.35 |
| ▸ | VDR | P11473 | 9/20 | 0.35 |
| ▸ | CDC25A | P30304 | 2/20 | 0.34 |
| ▸ | CDC25B | P30305 | 1/20 | 0.34 |
| ▸ | CYP27B1 | O15528 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329025 | 0.86 | VDR (0.37) | CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL12298784 | 0.85 | CYP24A1 (0.34) | SREBF1CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL12329127 | 0.82 | CYP24A1 (0.42) | SREBF1CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL12328982 | 0.76 | CYP24A1 (0.44) | CYP24A1VDR | |
| SCHEMBL12328981 | 0.76 | CYP24A1 (0.44) | CYP24A1VDR | |
| SCHEMBL12328983 | 0.76 | VDR (0.46) | SREBF1CYP24A1VDR | |
| SCHEMBL17354895 | 0.70 | VDR (0.38) | CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL17354881 | 0.70 | VDR (0.38) | CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL17354900 | 0.70 | VDR (0.38) | CYP24A1VDRCDC25ACDC25B | |
| SCHEMBL12298796 | 0.70 | VDR (0.42) | CYP24A1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645911-B2 | Such as 1-alpha-acetoxy-3,5-cyclo-(20S)-(diphenylphosphonium)-10-hydroxyl-cyclovitamin D2 1-acetate, 6-methyl ether; ozonolysis; dehydrogenation; crystallization | FORMOSA LABORATORIES, INC. (TW) | 2010-01-12 | — | — | US | disclosed |
| US-20090149678-A1 | PROCESS FOR PREPARATION OF PARICALCITOL AND INTERMEDIATES THEREOF | FORMOSA LABORATORIES, INC. (TW) | 2009-06-11 | — | — | US | disclosed |
| US-7491712-B1 | Process for preparation of paricalcitol and intermediates thereof | FORMOSA LABORATORIES, INC. (TW) | 2009-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149678-A1 | PROCESS FOR PREPARATION OF PARICALCITOL AND INTERMEDIATES THEREOF | CYP24A1, PTH1R, CYP2R1 | SREBF1 693/4885CYP24A1 1/4885VDR 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.